An observational study in Bullous Pemphigoid, sponsored by CHU de Reims. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-25.
Sponsored by CHU de Reims · Observational
Among 28 studies in Pemphigoid, Bullous with a site in France — 5 open to participants now, 6 under way, 1 of them phase 3. Pemphigoid, Bullous · France.
Among the 28 studies in Pemphigoid, Bullous with a site in France, this one is the 3rd largest by enrollment of the 11 observational ones that give a count, is one of 4 that started in 2013, is one of 11 observational ones, and was the 13th registered.
64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.
Browse Pemphigoid, Bullous studies →5 of the 28 studies in Pemphigoid, Bullous with a site in France are open now. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in France, United States, Australia and 17 more countries
Ages 18–85
University Hospital, Bordeaux · Sites in France
Ages 70+
CHU de Reims · Sites in France
Ages 18+
Chugai Pharmaceutical · Sites in France, Australia, Austria and 16 more countries
Ages 18–85
University Hospital, Rouen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 2
First in 2001; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 120 across 22 observational studies indexed under Pemphigoid, Bullous.
Median enrollment 67 across the 17 interventional studies, 122 across the 11 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 28 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 6 studies filed under Pemphigoid, Bullous — fewer than ten, so there is no comparison to draw.
2 of the studies in Pemphigoid, Bullous with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03295383Phase 3University Hospital, RouenRandomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | 2027-03 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Pemphigoid, Bullous with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Bullous pemphigoid affects mainly elderly patients. It is often associated with neurologic disorders, which represent a major risk factor of the disease
The aim was to determine whether neurologic disorders, especially dementia, influences outcome and mortality of patients with bullous pemphigoid.
All patients presenting bullous pemphigoid and consulting at dermatology department of Reims Teaching Hospital (France) between 1997 and 2011.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
Other: Data record
neurological disease
neurological disease are dementia (Alzheimers disease or other dementia), Parkinson's syndrome and stroke. Diagnosis of dementia was carried out in several ways: after examination by a neurologist or geriatrician, when the Mini Mental State was less than or equal to 17 or in the presence of a demonstrated and clinically evident dementia.
Time frame: Day 0
Ran from Oct 2013 to primary completion in Oct 2014, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.